Assessing pyridoxine adjuvant therapy effects on blood glucose levels in type 2 diabetes: A randomized clinical trial

Abstract

is the bioactive derivative of vitamin B6, functioning as a coenzyme in over 150 metabolic pathways. Insufficient PLP levels could be associated with the onset and progression of diabetes. This study aimed to assess the effects of pyridoxine adjuvant treatment on blood glucose levels in patients with type 2 diabetes mellitus (T2DM). This interventional, randomized, open-label study was conducted in the Mesan Governorate, with participants from the Mesan Center for Diabetes and Endocrinology as the study population. This study included patients newly diagnosed with T2DM. Patients were randomized into three groups: Group 1, the control group, treated with non-pharmacological therapy (lifestyle modification) (n=20); Group 2, treated with Metformin 500 mg/day in addition to non-pharmacological therapy (lifestyle modification) (n=20). Group 3 was treated with Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy (lifestyle modification) (n=68). The findings revealed a considerably favorable impact of pyridoxine adjuvant treatment with Metformin on blood glucose levels and other study variables. Compared to the patients in the control group G1, the reductions in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) were statistically significant in groups G2 and G3 after a 4-week treatment period. Similar results were observed for fasting serum insulin and homeostasis model assessment of insulin resistance (HOMA-IR) levels, with a significant decrease in groups G2 and G3 (p<0.05). Furthermore, the reductions in indoleamine 2,3-dioxygenase levels were also significantly higher in groups G2 and G3 at the end of the 4-week treatment period (-14.48% vs -21.16%) (p<0.05). Adding pyridoxine adjuvant therapy to Metformin treatment could effectively improve the blood glucose levels of patients with T2DM.

The Importance of Micronutrient Adequacy in Obesity and the Potential of Microbiota Interventions to Support It

“…For example, RCT with the participation of women with excess weight undergoing an 8-week weight reduction program (see Table 5) showed that such supplementation had a significant, positive effect on FI and HOMA-IR compared to the control group receiving a placebo [77]. In addition, other studies demonstrated lower postprandial glucose levels in healthy adults when vitamin B6 was administered 20 min before the oral glucose tolerance test (OGTT) [129] and a decrease of FG, FI, HOMA-IR, and HbA1c in T2D patients undergoing a 4-week supplementation [130]. In the la er study, the authors used vitamin B6 supplementation at a high dose of 300 mg/day compared to 80 mg/day and 50 mg/single dose in the former two studies.…”